MedTrace Logo

Gram-negative Bacteremia in HSCT Recipients

NCT02257931 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 591

Last updated 2017-05-01

No results posted yet for this study

Summary

A significant increase in resistant bacteria emerging in HSCT recipients. For example, 25% - 42% of all enterobacteriaceae produce extended spectrum beta-lactamases; 8 - 72% of Pseudomonas aeruginosa are resistant to at least one and 25 - 62% to three or more antibiotic classes, 13% of Gram-negative bacteria are caused by a multidrug-resistant (MDR) strain (Trecarichi JI 09, Mikulska BBMT 09, Oliveira BMT 07, Caselli Haemat 10, Gudiol, JAC 11). These resistant bacteria may be associated with increased mortality and have limited treatment options (Caselli Haemat 10, Poutsiaka BMT 07, DiazGranadoz JID 05). To provide the currently best empirical coverage and to control the growing resistance, knowledge of trends in antibiotic susceptibility, as well as risk factors is essential. For this reason we propose to perform non-interventional prospective multicentre study in EBMT centres.

Conditions

  • Allogeneic or Autologous HSCT

Sponsors & Collaborators

  • European Society for Blood and Marrow Transplantation

    lead NETWORK

Principal Investigators

  • Dina Averbuch, MD · Hadassah University Hospital, Pediatric Infectious Diseases Unit, Jerusalem, Israel

  • Dan Engelhard, MD · Hadassah University Hospital, Pediatric Infectious Diseases Unit, Jerusalem, Israel

  • Simone Cesaro, MD · Policlinico G.B. Rossi, paediatric haematology oncology, Verona, Italy

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-12-31
Completion
2017-04-30

Countries

  • Belgium
  • China
  • Croatia
  • Germany
  • Israel
  • Portugal
  • Russia
  • Sweden
  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02257931 on ClinicalTrials.gov